HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies.

导出 OA

翻译打印收藏纠错

作者： A Elisa,Pasqua ^[1] ; Swee Y,Sharp ^[1] ; Nicola E A,Chessum ^[1] ; Angela,Hayes ^[1] ; Loredana,Pellegrino ^[1] ; Michael J,Tucker ^[1] ; Asadh,Miah ^[1] ; Birgit,Wilding ^[1] ; Lindsay E,Evans ^[1] ; Carl S,Rye ^[1] ; N Yi,Mok ^[1] ; Manjuan,Liu ^[1] ; Alan T,Henley ^[1] ; Sharon,Gowan ^[1] ; Emmanuel,De Billy ^[1] ; Robert,Te Poele ^[1] ; Marissa,Powers ^[1] ; Suzanne A,Eccles ^[1] ; Paul A,Clarke ^[1] ; Florence I,Raynaud ^[1] ; Paul,Workman ^[1] ; Keith,Jones ^[1] ; Matthew D,Cheeseman ^[1]

作者单位： Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom. ^[1]

主题词人类(Humans);女(雌)性(Female);转录因子(Transcription Factors);卵巢肿瘤(Ovarian Neoplasms);细胞系, 肿瘤(Cell Line, Tumor);抗肿瘤药(Antineoplastic Agents)

DOI 10.1021/acs.jmedchem.3c00156

PMID 37017629

发布时间 2024-03-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交